spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   PAH 

 HSMN NewsFeed - 2 Jan 2024
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
Devices Regulatory FDA Reimbursement
 HSMN NewsFeed - 15 Nov 2022
Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Sep 2021
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 2 Oct 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Mar 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2018
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2018
United Therapeutics To Acquire SteadyMed Ltd.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Feb 2018
Grifols HyperRAB(R) (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2018
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2018
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Dec 2017
Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
Biopharmaceuticals FDA Licensing
 HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2017
BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2017
Johnson & Johnson Announces Completion of Acquisition of Actelion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Nov 2015
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin(TM) (ubenimex) for Inflammatory Diseases Involving LTB4
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Sep 2015
KARL STORZ’s New FLEX-GUARD System is Designed to Reduce Repair Costs of Flexible Ureterscopes
Devices Urology Product Launch
 HSMN NewsFeed - 15 Sep 2015
Bellerophon Therapeutics Announces Leadership Team Changes
Devices Drug Delivery Personnel
 HSMN NewsFeed - 18 Mar 2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2014
InterMune(R) Announces Support for First Ever European Patient Charter on Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals
 HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jul 2013
ARCA biopharma Announces Additions to GENETIC-AF Leadership Team
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 11 Feb 2013
Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2012
Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2010
Pfizer Stops Clinical Trials of Thelin(R) and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
Biopharmaceuticals
 HSMN NewsFeed - 25 Aug 2010
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI(R) (epoprostenol for injection) for Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 May 2010
Pfizer Enters Into Agreement With Ergonex Pharma to Acquire Investigational Treatment for Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Apr 2010
Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2010
United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jan 2010
European Commission Approves New Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 May 2009
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
Devices Cardiology
 HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Apr 2009
Merck Serono Launches Kuvan(R) in Europe
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2008
Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Nov 2008
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Nov 2008
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
Merck Serono's Kuvan(R) Recommended for European Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jun 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2008
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 29 May 2008
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2008
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Apr 2008
Medtronic Activa(R) Deep Brain Stimulation Patient Referral Advisor Software Launched in United States
Devices Neurology
 HSMN NewsFeed - 20 Feb 2008
Pfizer to Acquire Encysive Pharmaceuticals
Biopharmacetuicals Mergers & Acquisitions
 HSMN NewsFeed - 31 Jan 2008
Encysive Pharmaceuticals Launches THELIN (Sitaxentan Sodium) in Sweden
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
BioMarin Announces FDA Approval for Kuvan
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Nov 2007
Encysive Pharmaceuticals Launches Thelin (sitaxentan sodium) in Italy
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2007
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
Encysive Pharmaceuticals Announces Long-Term Study of Sitaxsentan Presented At Chest Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 24 Sep 2007
Encysive Pharmaceuticals to Conduct Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Biopharmaceuticals
 HSMN NewsFeed - 13 Aug 2007
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
Kuvan Receives Priority Review Status from FDA
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2007
Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium)
Biopharmaceuticals
 HSMN NewsFeed - 25 Jun 2007
Encysive Pharmaceuticals Appoints New Chief Executive and Announces Restructuring of Company Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2007
BioMarin Initiates Expanded Access Program for Kuvan in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
Bosentan (Tracleer) Receives EU Approval for Reduction of Number of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Apr 2007
Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2007
Proteo, Inc./Proteo Biotech AG: European Commission grants Orphan Drug Status to Elafin for the treatment of PAH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Mar 2007
United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan
Biopharmaceuticals Distribution
 HSMN NewsFeed - 26 Mar 2007
Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 8 Dec 2006
Actelion Ltd. Announces Commencement of Cash Tender Offer for CoTherix, Inc. and HSR Clearance to Acquire CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Oct 2006
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Sep 2006
Merck and Nicaragua Unveil New Rotavirus Vaccine Demonstration Project at Clinton Global Initiative
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2006
Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2006
CoTherix Licenses Exclusive Rights to Develop and Commercialize Oral and Inhaled Formulations of Fasudil for the Treatment of PAH and Stable Angina in North America and Europe From Asahi Kasei Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Jun 2006
Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 May 2006
Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Actelion: ATS Presentation Highlights Strong Rationale for a Morbidity/Mortality Study with Bosentan in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 71

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 71 additional stories matching:
PAH
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.